



(12) **CORRECTED EUROPEAN PATENT SPECIFICATION**

(15) Correction information:
Corrected version no 1 (W1 B1)
Corrections, see
Bibliography INID code(s) 73

(48) Corrigendum issued on:
21.06.2023 Bulletin 2023/25

(45) Date of publication and mention
of the grant of the patent:
10.05.2023 Bulletin 2023/19

(21) Application number: **17821125.6**

(22) Date of filing: **28.06.2017**

(51) International Patent Classification (IPC):
A61K 9/00 ^(2006.01) **A61K 9/48** ^(2006.01)
A61K 9/50 ^(2006.01) **A61K 47/32** ^(2006.01)
A61P 1/00 ^(2006.01) **A61P 1/04** ^(2006.01)
A61P 1/12 ^(2006.01) **A61P 29/00** ^(2006.01)
A61P 31/04 ^(2006.01) **A61P 39/00** ^(2006.01)
A61P 39/02 ^(2006.01) **A61P 43/00** ^(2006.01)
A61K 31/424 ^(2006.01) **A61K 45/06** ^(2006.01)
A61K 38/50 ^(2006.01)

(52) Cooperative Patent Classification (CPC):
(C-Sets available)
A61K 9/5078; A61K 9/0053; A61K 9/4891;
A61K 9/5026; A61K 31/424; A61K 38/50;
A61K 45/06; A61K 47/32; A61P 1/00; A61P 1/04;
A61P 1/12; A61P 29/00; A61P 31/04; A61P 39/00;
A61P 39/02; (Cont.)

(86) International application number:
PCT/US2017/039672

(87) International publication number:
WO 2018/005606 (04.01.2018 Gazette 2018/01)

(54) **MICROBIOME PROTECTION FROM ORAL ANTIBIOTICS**

SCHUTZ DER DARMSFLORA VOR ORALEN ANTIBIOTIKA

PROTECTION DU MICROBIOME CONTRE LES ANTIBIOTIQUES ORAUX

(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB
GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO
PL PT RO RS SE SI SK SM TR

(30) Priority: **28.06.2016 US 201662355599 P**

(43) Date of publication of application:
01.05.2019 Bulletin 2019/18

(73) Proprietor: **Theriva Biologics, Inc.**
Rockville, MD 20850 (US)

(72) Inventors:
• **KALEKO, Michael**
Rockville, MD 20850 (US)
• **CONNELLY, Sheila**
Rockville, MD 20850 (US)

(74) Representative: **Boxall, Sarah Jane**
Boxall IPM Ltd
9 King Street
Sandwich Kent CT13 9BT (GB)

(56) References cited:
WO-A1-2008/065247 WO-A1-2011/148041
WO-A1-2016/057744 WO-A1-2016/137993
WO-A2-2015/161243 US-B2- 8 273 376

• **KALEKO, M ET AL.: 'Development of SYN-004, an oral beta-lactamase treatment to protect the gut microbiome from antibiotic-mediated damage and prevent Clostridium difficile infection'**
ANAEROBE vol. 41, 02 June 2016, pages 58 - 67,
XP055444836

Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

(52) Cooperative Patent Classification (CPC): (Cont.)
A61P 43/00; C12Y 305/02006

C-Sets

A61K 31/424, A61K 2300/00